On Nov 15, major Wall Street analysts update their ratings for $Tarsus Pharmaceuticals (TARS.US)$, with price targets ranging from $65 to $84.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and maintains the target price at $68.
Oppenheimer analyst Francois Brisebois maintains with a buy rating, and adjusts the target price from $63 to $65.
H.C. Wainwright analyst Oren Livnat maintains with a buy rating, and adjusts the target price from $61 to $73.
LifeSci Capital analyst Cory Jubinville, PhD maintains with a buy rating, and adjusts the target price from $67 to $84.
Furthermore, according to the comprehensive report, the opinions of $Tarsus Pharmaceuticals (TARS.US)$'s main analysts recently are as follows:
Tarsus Pharmaceuticals' third-quarter EPS exceeded expectations, with a significant beat on Xdemvy net product sales reaching $48.1M, though the number of vials dispensed aligned with forecasts. The company's discussion during the call was centered on a more positive forecast for Xdemvy in the fourth quarter and subsequent periods, following the expansion of the sales team.
Tarsus Pharmaceuticals reported a third-quarter topline of $48.1M, surpassing both the anticipated $44.3M and the consensus estimate of $43M, showcasing a robust growth of 40%. The company's advancements with target ECPs are noteworthy, with over 13,000 ECPs already prescribing Xdemvy. It's expected that Tarsus' efforts will continue to propel Xdemvy's growth. Positive data concerning MGD has been met with enthusiasm, and there is an anticipation for the company's strategic approach to commercialization.
Here are the latest investment ratings and price targets for $Tarsus Pharmaceuticals (TARS.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月15日，多家華爾街大行更新了$Tarsus Pharmaceuticals (TARS.US)$的評級，目標價介於65美元至84美元。
美銀證券分析師Jason Gerberry維持買入評級，維持目標價68美元。
奧本海默控股分析師Francois Brisebois維持買入評級，並將目標價從63美元上調至65美元。
H.C. Wainwright分析師Oren Livnat維持買入評級，並將目標價從61美元上調至73美元。
LifeSci Capital分析師Cory Jubinville, PhD維持買入評級，並將目標價從67美元上調至84美元。
此外，綜合報道，$Tarsus Pharmaceuticals (TARS.US)$近期主要分析師觀點如下：
tarsus pharmaceuticals第三季度每股收益超出預期，Xdemvy淨產品銷售額達到4810萬美元，儘管散發的小瓶數量與預期一致。公司在電話會議期間的討論集中在對第四季度和隨後幾期Xdemvy的更爲樂觀預測上，隨着銷售團隊的擴大。
tarsus pharmaceuticals報告第三季度營收4810萬美元，超過預期的4430萬美元和市場一致估計的4300萬美元，展現了40%的強勁增長。該公司在目標ECPs方面的進展值得關注，已有超過13,000名ECPs處方Xdemvy。預計tarsus的努力將繼續推動Xdemvy的增長。關於MGD的積極數據受到熱情迎接，人們期待公司在商業化方面的戰略舉措。
以下爲今日4位分析師對$Tarsus Pharmaceuticals (TARS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
